143 related articles for article (PubMed ID: 12667341)
21. Mitoxantrone-DHAP with GM-CSF: an active but myelosuppressive salvage therapy for relapsed/refractory aggressive non-Hodgkin's lymphoma.
Haq R; Sawka CA; Franssen E; Berinstein NL
Leuk Lymphoma; 1999 Nov; 35(5-6):527-36. PubMed ID: 10609790
[TBL] [Abstract][Full Text] [Related]
22. Gemcitabine, dexamethasone, and cisplatin in patients with recurrent or refractory aggressive histology B-cell non-Hodgkin lymphoma: a Phase II study by the National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG).
Crump M; Baetz T; Couban S; Belch A; Marcellus D; Howson-Jan K; Imrie K; Myers R; Adams G; Ding K; Paul N; Shepherd L; Iglesias J; Meyer R
Cancer; 2004 Oct; 101(8):1835-42. PubMed ID: 15386331
[TBL] [Abstract][Full Text] [Related]
23. Gemcitabine, cisplatin and methylprednisolone chemotherapy (GEM-P) is an effective regimen in patients with poor prognostic primary progressive or multiply relapsed Hodgkin's and non-Hodgkin's lymphoma.
Chau I; Harries M; Cunningham D; Hill M; Ross PJ; Archer CD; Norman AR; Wotherspoon A; Koh DM; Gill K; Uzzell M; Prior Y; Catovsky D
Br J Haematol; 2003 Mar; 120(6):970-7. PubMed ID: 12648066
[TBL] [Abstract][Full Text] [Related]
24. Gemcitabine, dexamethasone and cisplatin is an active and non-toxic chemotherapy regimen in relapsed or refractory Hodgkin's disease: a phase II study by the National Cancer Institute of Canada Clinical Trials Group.
Baetz T; Belch A; Couban S; Imrie K; Yau J; Myers R; Ding K; Paul N; Shepherd L; Iglesias J; Meyer R; Crump M
Ann Oncol; 2003 Dec; 14(12):1762-7. PubMed ID: 14630682
[TBL] [Abstract][Full Text] [Related]
25. [The role of gemcitabine in hematology].
Dumontet C
Bull Cancer; 2002 Aug; 89 Spec No():S123-6. PubMed ID: 12449043
[TBL] [Abstract][Full Text] [Related]
26. Gemcitabine, cisplatin and methylprednisolone (GEM-P) is an effective salvage regimen in patients with relapsed and refractory lymphoma.
Ng M; Waters J; Cunningham D; Chau I; Horwich A; Hill M; Norman AR; Wotherspoon A; Catovsky D
Br J Cancer; 2005 Apr; 92(8):1352-7. PubMed ID: 15812553
[TBL] [Abstract][Full Text] [Related]
27. [Treatment effect of DICE regimen on patients with relapsed or refractory intermediate and high grade non-Hodgkin's lymphoma].
Zhou SY; Shi YK; He XH; Zhang P; Dong M; Huang DZ; Yang JL; Zhang CG; Liu P; Yang S; Feng FY
Ai Zheng; 2005 Apr; 24(4):465-9. PubMed ID: 15820071
[TBL] [Abstract][Full Text] [Related]
28. Gemcitabine alone or combined with cisplatin in relapsed or refractory multiple myeloma.
Offidani M; Mele A; Corvatta L; Marconi M; Malerba L; Olivieri A; Rupoli S; Alesiani F; Leoni P
Leuk Lymphoma; 2002 Jun; 43(6):1273-9. PubMed ID: 12152996
[TBL] [Abstract][Full Text] [Related]
29. Cisplatin, fludarabine, and cytarabine: a novel, pharmacologically designed salvage therapy for patients with refractory, histologically aggressive or mantle cell non-Hodgkin's lymphoma.
Seymour JF; Grigg AP; Szer J; Fox RM
Cancer; 2002 Feb; 94(3):585-93. PubMed ID: 11857288
[TBL] [Abstract][Full Text] [Related]
30. Salvage chemotherapy of gemcitabine, dexamethasone, and cisplatin (GDP) for patients with relapsed or refractory peripheral T-cell lymphomas: a consortium for improving survival of lymphoma (CISL) trial.
Park BB; Kim WS; Suh C; Shin DY; Kim JA; Kim HG; Lee WS
Ann Hematol; 2015 Nov; 94(11):1845-51. PubMed ID: 26251158
[TBL] [Abstract][Full Text] [Related]
31. [Preliminary outcome for patients with relapsed or resistant advanced non-Hodgkin's lymphoma treated by EPOCH regimen].
Huang HQ; Jiang WQ; Wang W; Zhou ZM; Xia ZJ; Lin XB; Li YH; Xu RH; Zhang L; Xu GC; Sun XF; Liu DG; He YJ; Guan ZZ
Ai Zheng; 2003 Apr; 22(4):389-92. PubMed ID: 12703995
[TBL] [Abstract][Full Text] [Related]
32. Gemcitabine, vinorelbine and dexamethasone: A safe and effective regimen for treatment of relapsed/refractory hodgkin's lymphoma.
Ganesan P; Mehra N; Joel A; Radhakrishnan V; Dhanushkodi M; Perumal Kalayarasi J; Kannan K; Ganesan TS; Sagar TG
Leuk Res; 2019 Sep; 84():106188. PubMed ID: 31325732
[TBL] [Abstract][Full Text] [Related]
33. Gemcitabine and its combinations in the treatment of malignant lymphoma.
Chau I; Watkins D; Cunningham D
Clin Lymphoma; 2002 Sep; 3(2):97-104. PubMed ID: 12435288
[TBL] [Abstract][Full Text] [Related]
34. Salvage chemotherapy with mitoxantrone, fludarabine, cytarabine, and cisplatin (MIFAP) in relapsing and refractory lymphoma.
Hänel M; Kröger N; Kroschinsky F; Birkmann J; Hänel A; Herbst R; Naumann R; Friedrichsen K; Ehninger G; Zander AR; Fiedler F
J Cancer Res Clin Oncol; 2001; 127(6):387-95. PubMed ID: 11414199
[TBL] [Abstract][Full Text] [Related]
35. Etoposide, mitoxantrone and prednisone: a salvage regimen with low toxicity for refractory or relapsed non-Hodgkin's lymphoma.
Doorduijn JK; Spruit P; van Der Holt B; van't Veer M; Budel L; Löwenberg B; Sonneveld P
Haematologica; 2000 Aug; 85(8):814-9. PubMed ID: 10942927
[TBL] [Abstract][Full Text] [Related]
36. Phase II study of low-dose fixed-rate infusion of gemcitabine combined with cisplatin and dexamethasone in resistant non-Hodgkin lymphoma and correlation with Bcl-2 and MDR expression.
Elsamany S; Farooq MU; Elsirafy M; Shamaa S; Sakr M
Med Oncol; 2014 Mar; 31(3):872. PubMed ID: 24496564
[TBL] [Abstract][Full Text] [Related]
37. [DNCE regimen for treatment of refractory or relapsed aggressive and highly aggressive non-Hodgkin lymphoma].
Liu XM; Wang HQ; Zhang HL; Qiu LH; Li W; Li LF; Cui XZ; Liu PF; Hao XS
Zhonghua Zhong Liu Za Zhi; 2008 Oct; 30(10):779-82. PubMed ID: 19173813
[TBL] [Abstract][Full Text] [Related]
38. [Outpatient reinduction therapy with gemcitabine, dexamethasone, Cisplatin (GDP) for patients with relapsed and refractory lymphoma].
Aota Y; Tanaka M; Watanabe N; Tomomatu J; Gotoh A; Komatu N
Gan To Kagaku Ryoho; 2015 Jan; 42(1):51-5. PubMed ID: 25596679
[TBL] [Abstract][Full Text] [Related]
39. Rituximab plus ASHAP for the treatment of patients with relapsed or refractory aggressive non-Hodgkin's lymphoma: a single-centre study of 20 patients.
Aydin S; Dührsen U; Nückel H
Ann Hematol; 2007 Apr; 86(4):271-6. PubMed ID: 17216473
[TBL] [Abstract][Full Text] [Related]
40. Radiotherapy does not influence the severe pulmonary toxicity observed with the administration of gemcitabine and bleomycin in patients with advanced-stage Hodgkin's lymphoma treated with the BAGCOPP regimen: a report by the German Hodgkin's Lymphoma Study Group.
Macann A; Bredenfeld H; Müller RP; Diehl V; Engert A; Eich HT
Int J Radiat Oncol Biol Phys; 2008 Jan; 70(1):161-5. PubMed ID: 17855012
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
